Non-steroid agents for idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Non-steroid agents for idiopathic pulmonary fibrosis

Published:2010-09-08 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Spagnolo Paolo¹,Del Giovane Cinzia²,Luppi Fabrizio³,Cerri Stefania¹,Balduzzi Sara²,Walters E. Haydn⁴,D'Amico Roberto²,Richeldi Luca¹

Affiliation:

1. University of Modena and Reggio Emilia; Center for Rare Lung Disease, University of Modena and Reggio Emilia, Modena Italy and Respiratory Disease Section, Department of Oncology, Hematology and Respiratory Disease; Modena Italy

2. University of Modena and Reggio Emilia; Statistics Unit, Department of Oncology, Hematology and Respiratory Disease; Modena Italy

3. Center for Rare Lung Disease, University of Modena and Reggio Emilia, Modena Italy and Respiratory Disease Section, Department of Oncology, Hematology and Respiratory Disease Azienda Ospedaliero-Universitaria di Modena; Modena Italy

4. University of Tasmania; Menzies Research Institute; MS1, 17 Liverpool Street PO Box 23 Hobart Tasmania Australia 7001

Publisher

Wiley

Subject

Pharmacology (medical)

Reference147 articles.

1. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis;Azuma;American Journal of Respiratory and Critical Care Medicine,2005

2. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis;King;American Journal of Respiratory and Critical Care Medicine,2008

3. A randomised, double-blind, placebo-controlled, phase III study of the safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis Data on file

4. A randomised, double-blind, placebo-controlled, phase III, three-arm study of the safety and efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis Data on file

5. Imatinib treatment for idiopathic pulmonary fibrosis. Randomized placebo-controlled trial results;Daniels;American Journal of Respiratory and Critical Care Medicine,2010

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary Fibrosis: Unveiling the Pathogenesis, Exploring Therapeutic Targets, and Advancements in Drug Delivery Strategies;AAPS PharmSciTech;2023-07-13

2. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version;Respiratory Medicine and Research;2023-06

3. Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2;Life Sciences;2022-11

4. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2021. Version intégrale;Revue des Maladies Respiratoires;2022-09

5. β-Carboline Alkaloids From the Deep-Sea Fungus Trichoderma sp. MCCC 3A01244 as a New Type of Anti-pulmonary Fibrosis Agent That Inhibits TGF-β/Smad Signaling Pathway;Frontiers in Microbiology;2022-07-28